Elanco Animal Health (ELAN) Stock Overview
An animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ELAN from our risk checks.
ELAN Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Elanco Animal Health Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.08 |
| 52 Week High | US$27.72 |
| 52 Week Low | US$8.02 |
| Beta | 1.89 |
| 1 Month Change | -7.23% |
| 3 Month Change | 2.49% |
| 1 Year Change | 137.45% |
| 3 Year Change | 153.07% |
| 5 Year Change | -22.03% |
| Change since IPO | -35.89% |
Recent News & Updates
Recent updates
Elanco Animal Health (ELAN) Unleashing the Pipeline: Can New Launches Lead the Pack?
Elanco (ELAN) is entering a critical execution phase as of late February 2026, with the stock currently trading at $24.98. Following its successful strategic pivot away from low-margin legacy products, the company is now fully centered on its high-growth "Innovation" pillar.Elanco Animal Health: Innovation-Led Growth Model Plus Credible Deleveraging Path
Jan 09Elanco Animal Health's (NYSE:ELAN) Profits Appear To Have Quality Issues
Aug 20
Elanco Animal Health (NYSE:ELAN) Has A Somewhat Strained Balance Sheet
Jul 21Elanco Animal Health Incorporated (NYSE:ELAN) Held Back By Insufficient Growth Even After Shares Climb 39%
May 28The Market Doesn't Like What It Sees From Elanco Animal Health Incorporated's (NYSE:ELAN) Revenues Yet As Shares Tumble 25%
Apr 09Elanco Animal Health: Even Cheaper, Still Not A Buy
Mar 31
Zenrelia And Credelio Quattro Launches Will Expand Market Presence But FX Headwinds May Impact Earnings
Strategic divestment and product launches are enhancing financial stability by reducing debt and increasing investment capacity, aiming to improve net margins.Elanco Animal Health: Building On Success
Jan 15Elanco Animal Health: Not Expensive, But Debt Remains An Issue
Nov 08Elanco Animal Health: Positioned For Success
Aug 16Shareholder Returns
| ELAN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.1% | 2.9% | -0.3% |
| 1Y | 137.4% | 29.1% | 16.1% |
Return vs Industry: ELAN exceeded the US Pharmaceuticals industry which returned 29.1% over the past year.
Return vs Market: ELAN exceeded the US Market which returned 16.1% over the past year.
Price Volatility
| ELAN volatility | |
|---|---|
| ELAN Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ELAN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ELAN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 9,650 | Jeff Simmons | www.elanco.com |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry.
Elanco Animal Health Incorporated Fundamentals Summary
| ELAN fundamental statistics | |
|---|---|
| Market cap | US$11.49b |
| Earnings (TTM) | -US$232.00m |
| Revenue (TTM) | US$4.72b |
Is ELAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELAN income statement (TTM) | |
|---|---|
| Revenue | US$4.72b |
| Cost of Revenue | US$2.12b |
| Gross Profit | US$2.59b |
| Other Expenses | US$2.83b |
| Earnings | -US$232.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 54.99% |
| Net Profit Margin | -4.92% |
| Debt/Equity Ratio | 62.1% |
How did ELAN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/02 21:52 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elanco Animal Health Incorporated is covered by 27 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Glen Santangelo | Barclays |
| Ardalan Arfaei | BMO Capital Markets Equity Research |